Preliminary Scientific Program
ΠΑΡΑΣΚΕΥΗ 11 ΣΕΠΤΕΜΒΡΙΟΥ 2015 15.30 – 16.00 Welcome and Chair Remarks
V. Georgoulias – University of Crete 16.00 – 16.50 Breast Cancer – HER2/ER – ER+ - HER2+
Chair: V. Barbounis 16.00 – 16.15 Presenter 1: E. Saloustros
Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.
Title:PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.
16.15 – 16.30 Presenter 2: E. Galani
Title: Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.
Title: Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).
16.30 – 16.40 Discussant: D. Tryfonopoulos 16.40 – 16.50 General Discussion
16.50 – 17.50 Breast Cancer – Triple Negative/Cytotoxics/Local Therapy Chair: Ch. Papadimitriou
16.50 – 17.05 Presenter 1: N. Xenidis
Title: Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician’s Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study.
Title: Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).
17.05 – 17.25 Presenter 2: M. Nikolaidi
Title: Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials.
Title: Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC).
Title: The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast.
17.25 – 17.40 Discussant: D. Mavroudis 17.40 – 17.50 General Discussion 17.50 – 18.20 Coffee Break 18.20 – 19.10 Melanoma Chair: D. Bafaloukos 18.15 – 18.30 Presenter 1: A. Boutis
Title: Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).
Title: Long term follow up of survival in a randomised trial of wide or narrow excision margins in high risk primary melanoma.
18.30 – 18.45 Presenter 2: F. Stavridi
Title: Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma.
Title: Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: A multicenter, randomized DECOG trial.
18.45 – 19.00 Discussant: TBC 19.00 – 19.10 General Discussion 19.10 – 19.50 Sarcoma Chair: I. Boukovinas 19.10 – 19.25 Presenter: A. Laskarakis 19.25 – 19.40 Discussant: TBC 19.40 – 19.50 General Discussion
19.50 – 20.40 Patient and Survivor Care Chair: A. Christopoulou 19.50 – 20.05 Presenter 1: TBC
Title: Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.
Title: Phase III trials of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (ROMANA 1 and 2).
Title: CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.
20.05 – 20.20 Presenter 2: Ε. Maragouli
Title: Long-term safety of fertility preservation by ovarian stimulation and concurrent aromatase inhibitor treatment in women with breast cancer.
Title: Oral nicotinamide to reduce actinic cancer: A phase 3 double-blind randomized controlled trial.
20.20 – 20.35 Discussant: TBD 20.35 – 20.40 General Discussion
21.00 D i n n e r
ΣΑΒΒΑΤΟ 12 ΣΕΠΤΕΜΒΡΙΟΥ 2015 09.00 – 09.55 Gastrointestinal (Colorectal) Cancer
Chair: P. Papakostas 09.00 – 09.15 Presenter 1: Z. Saridaki
Title: The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast.
Title: Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC).
Title: SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC).
09.15 – 09.30 Presenter 2: M. Theochari
Title: Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance).
Title: Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: A population-based study.
09.30 – 09.45 Discussant: Th. Makatsoris 09.45 – 09.55 General Discussion
09.55 – 10.30 Gastrointestinal (Non-Colorectal) Cancer Chair: Ch. Panopoulos
09.55 – 10.10 Presenter : K. Ploiarchopoulou
Title: Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.
Title: Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012.
Title: Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).
10.10 – 10.20 Discussant: Ch. Kourousis 10.20 – 10.30 General Discussion 10.30 – 11.00 Coffee Break 11.00 – 11.40 Gynecologic Cancer Chair: Ch. Christofyllakis 11.00 – 11.10 Presenter 1: TBD
Title: A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and
ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.
Title: Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.
11.10 – 11.20 Presenter 2: I. Syrios
Title: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.
Title: CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ECOG-ACRIN and NRG GOG study.
11.20 – 11.30 Discussant: E. Timotheadou 11.30 – 11.40 General Discussion
11.40 – 12.50 Genitourinary Cancer Chair: D. Daliani
11.40 – 11.50 Presenter 1: S. Stamatopoulou
Title: Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476).
Title: A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and
prednisone for localized, high-risk prostate cancer (RTOG 0521).
Title: Defining a molecular subclass of treatment resistant prostate cancer.
11.50 – 12.00 Presenter 2: G. Economopoulou
Title: Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial—NCT00423475.
Title: TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial.
12.00 – 12.10 Discussant: E. Bournakis 12.10 – 12.20 Presenter 3: E. Lianos
Title: First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial.
Title: A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients.
12.20 – 12.30 Presenter 4: V. Rizouli
Title: Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC).
Title: Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).
12.30 – 12.40 Discussant: A. Bamias 12.40 – 12.50 General Discussion
12.50 – 13.40 Head and Neck Cancer Chair: A. Argyris
12.50 – 13.05 Presenter 1: E. Douvelis
Title: Elective versus therapeutic neck dissection in the clinically node negative early oral cancer: A randomised control trial (RCT).
Title: Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial.
Title: Prognostic implication of persistent HPV16 DNA detection in oral rinses for HPV-positive oropharyngeal carcinoma.
13.05 – 13.20 Presenter 2: A. Tzovaras
Title: Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.
Title: PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical
chemoradiotherapy (CRT).
13.20 – 13.30 Discussant: I. Athanasiadis 13.30 – 13.40 General Discussion
13.40-15.00 Lunch
15.00 – 16.00 Lung Cancer Non-Small Cell Lung Cancer: Metastatic Chair: E. Samantas
15.00 – 15.10 Presenter 1: V. Karavassilis
Title: NCCTG N0574 (Alliance): A phase III randomized trial of whole brain
radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases.
Title: Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).
15.10 – 15.20 Presenter 2: P. Katsaounis
Title: Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).
Title: Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical
Research Council QUARTZ randomised clinical trial (ISRCTN 3826061).
15.20 – 15.30 Presenter 3: Ph. Koinis
Title: Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).
Title: Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).
15.30 – 15.50 Discussant: S. Agelaki 15.50 – 16.00 General Discussion
16.00 – 16.30 Coffee Break
16.30 – 17.20 Lung Cancer Non-Small Cell Local-Regional/Small Cell Chair: N. Kentepozidis
16.30 – 16.40 Presenter 1: S. Peroukidis
Title: Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial.
Title: Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028.
16.40 – 16.55 Presenter 2: S. Kaltsas
Title: Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.
Title: Final overall survival (OS) results of the phase III PROCLAIM trial:
Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC).
Title: Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial
(Eudract:2007-000067-15; NCTgov: 00478699).
16.55 – 17.10 Discussant: M. Vaslamatzis 17.10 – 17.20 General Discussion
17.20 – 18.00 Educational Session: Tumor Immunology Chair: A. Kotsakis Presenter: M. Liontos General Discussion 18.00 – 19.10 Developmental Therapeutics Chair: A. Psyrri 18.00 – 18.10 Presenter 1: E. Kontopodis
Title: Successful implementation of a novel trial model: The Signature program.
Title: A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers.
18.10 – 18.20 Presenter 2: N. Diamantopoulos
Title: Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.
Title: A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL.
18.20 – 18.35 Discussant: A. Koutras 18.35 – 18.45 Presenter 3: ΤΒD
Title: Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.
Title: Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).
18.45 – 18.55 Discussant: J. Janinis 18.55 – 19.10 General Discussion